Klimadynon

Cimicifuga racemosa dry extract, the active ingredient in Klimadynon, is a herbal botanical presented as a dry extract for oral use. It is traditionally employed to alleviate menopausal discomfort, including hot flashes, night sweats, and mood fluctuations in adult women, and is also explored for premenstrual syndrome support.

GNH USA supplies Klimadynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across European and global markets through rigorous manufacturing standards and validated analytical testing.

Klimadynon, a black cohosh dry extract, is used to address symptoms associated with the menopausal transition.

- Hot flashes: reduction in frequency and intensity - Night sweats: decreased episodes and improved sleep quality - Mood swings: improvement in emotional stability and reduced irritability

Klimadynon may cause a range of adverse reactions.

Common Side Effects: - Mild gastrointestinal upset: nausea, stomach discomfort - Headache: transient and usually mild - Dizziness: occasional light‑headedness

Serious or Rare Side Effects: - Liver enzyme elevation: possible hepatic involvement - Allergic reaction: rash, itching, or swelling - Severe abdominal pain: should prompt medical evaluation

Use Klimadynon with awareness of the following precautions.

- Pregnancy: safety not established, avoid use unless advised - Breastfeeding: caution advised due to limited data - Known hypersensitivity: discontinue if allergic reactions occur - Concurrent hormone therapy: monitor for possible antagonistic effects - Liver disease: use with caution and monitor liver function - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight

Klimadynon may interact with other medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk - Hormone replacement therapy: possible antagonistic effect on estrogen pathways

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs): potential serotonergic interaction - CYP450 substrate drugs: possible alteration of metabolism - Diuretics: may increase potassium loss, monitor electrolytes